COEP
Coeptis Therapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Stock Price Surged Significantly
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About COEP
Coeptis Therapeutics Holdings, Inc.
A biopharmaceutical company that developing innovative cell therapy platforms for cancer
Life Science Tools and Services
11/27/2018
12/17/2020
NASDAQ Stock Exchange
7
12-31
Common stock
105 Bradford Rd, Suite 420, Wexford, Pennsylvania 15090
--
Coeptis Therapeutics Holdings, Inc., was originally incorporated in the British Virgin Islands on November 27, 2018 and moved to Delaware on October 27, 2022. The company operates as a holding company and manages a series of subsidiaries focused on biopharmaceutical development. Its business model focuses on advancing the product portfolio through strategic cooperation, which may include authorized introduction, co-development and other collaborative arrangements in therapeutic areas such as oncology, respiratory virus infection and autoimmune diseases.
Company Financials
EPS
COEP has released its 2025 Q3 earnings. EPS was reported at -0.58, versus the expected 0, missing expectations. The chart below visualizes how COEP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
COEP has released its 2025 Q3 earnings report, with revenue of 237.44K, reflecting a YoY change of NaN%, and net profit of -2.90M, showing a YoY change of -58.50%. The Sankey diagram below clearly presents COEP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
